News Sentiment

VYGR sentiment intelligence

Voyager Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.44 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-9.0% over one week, -1.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -9.0% Price reacting lower
Trend fit Trend inactive -1.7% over four weeks
Fair value -40.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 35
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 10
Stock Titan 7
GlobeNewswire 5
simplywall.st 5
Moomoo 2
Investing.com 2
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 15
Regulatory and legal 8
Analyst action 4
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
TradingView Direct company coverage

Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR)

This article provides an overview of Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock performance, financial actuals and estimates, and analyst forecasts. It details current stock price, volatility, market capitalization, earnings, and revenue, alongside historical highs and lows.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:39
Source
TradingView
The Globe and Mail Direct company coverage

H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) with a $25.00 price target. This follows a previous Buy rating from TD Cowen. The company reported a Q1 revenue of $2.59 million and a net loss of $27.94 million, while corporate insid

Tone
Positive 67/100
Event
Analyst action
Published
26 Jun 2026 13:10
Source
The Globe and Mail
TradingView Direct company coverage

Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6)

This article provides an overview of Voyager Therapeutics, Inc. (VT6), including its financial actuals and estimates, stock forecast, and historical price data. It details the company's past earnings and revenue performance, along with analyst predictions for future quarters. The

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 16:09
Source
TradingView
TradingKey Direct company coverage

Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), identifying its major shareholders and their respective proportions, such as Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice Capital LLC. It also presents a breakdown of shareholder t

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 01:10
Source
TradingKey